NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers

Brooker, RC ORCID: 0000-0002-0668-6889, Schache, AG ORCID: 0000-0001-9466-6038 and Sacco, JJ (2021) NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 59 (8). pp. 959-962.

Text
Brooker 2020 BJOMS_NICO short communication.pdf - Author Accepted Manuscript
Download (1MB) | Preview

Official URL: http://dx.doi.org/10.1016/j.bjoms.2020.08.059

Abstract

Outcomes remain poor for patients presenting with locally-advanced oral cancers and it remains imperative to re-evaluate adjuvant therapies to provide improved outcomes, ideally without compromising on long-term quality of life. We present current available evidence that supports the use of immune checkpoint inhibitors (ICI) in squamous cell carcinoma (SCC) of the head and neck and discuss trials examining the integration of ICI into the locoregional management of such lesions that are resectable. We focus particularly on the Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer (NICO) trial which is investigating the integration of neoadjuvant and adjuvant ICI into the treatment of resectable locally-advanced oral cavity cancers.

Item Type:	Article
Uncontrolled Keywords:	Oral Cancer, squamous cell cancer, immune checkpoint inhibitors, immunotherapy, chemoradiotherapy, adjuvant
Depositing User:	Symplectic Admin
Date Deposited:	18 Sep 2020 10:11
Last Modified:	18 Jan 2023 23:32
DOI:	10.1016/j.bjoms.2020.08.059
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3101657